Option chain shows key data for Viridien ADR's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Viridien ADR.

Viridien ADR (OTC:CGGYY) Stock, Option Chain

News

Intraday Update

Markets

Movers

Trading Ideas

AAPL

AAVXF

ACLS

ADBE

AFGC

AHEXY

AHFD

AINV

AIQUY

ALAC

AMGN

ANSLY

APAM

AQUA

ARES

ARGX

ARNC

ASBFY

ASGN

ASMIY

ASML

ATLKY

AUDC

BABA

BAESF

BAESY

BCLYF

BNPQY

BNTGF

BNTGY

BRPM

BTDPY

BVXV

CARO

CATWF

CBGPY

CBSH

CCGGY

CDMO

CEBUY

CGGYY

CKNHF

CMRE

CODYY

COHU

CRAI

CRARY

CRHCF

CRUS

CSTM

CTIC

CTON

DGDM

DIOD

DKILY

DPSGY

DRNA

DRTGF

DRUNF

DSDVY

DSKIF

DSNKY

Stocks That Hit 52-Week Highs On Friday

AACAF

AACAY

AGPPF

AHAG

ALFVY

AMCI

AMTBB

ANGPY

APRE

APTO

ARLUF

AROW

ARVN

ASMVY

ATLKF

ATVI

AUCOY

AUPH

AVGO

BANF

BLDR

BNTX

BPIGF

BPXXY

BRBOF

BRK-A

BRK-B

BRKL

CALB

CARE

CBRE

CGECF

CHDN

CNOB

CPXWF

CTBI

CTXXF

Stocks That Hit 52-Week Highs On Thursday

ABLZF

ACNFF

AGESY

AGRO

AIMT

ALBY

ALCO

ALLE

ARQL

ARRJF

ASCC

ATAZF

ATBYF

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

BBIO

BCUCY

BCVVF

BKFKF

BOCH

BOLD

BRBR

BRMK

BSDGY

BUKS

BXMT

BYAGF

BYDIF

CGOOF

CHGCY

CMCXF

CODI

CSIOY

CUBA

DCPH

DFCO

DPMLF

EBMT

EFIN

EIDX

ESKYF

EXPR

FFBW

FLXN

FMNB

Cohen & Steers Closed-End Opportunity Fund

FRRVY

FSBW

FSUGY

FSUMF

FTSV

FXTGY

GBERY

GBNXF

GFED

GLPG

GMRE

GOSS

CERRO DE PASCO RES INC by Cerro De Pasco Res Inc.

GPPRF

GSAH

GSBD

Stocks That Hit 52-Week Highs On Tuesday

Viridien ADR

Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) climbed 4.2% during the pre-market trading session on Friday following strong financial performance for the third quarter.
What Happened: The Chinese tech giant posted stellar results for the December quarter surpassing expectations. Alibaba&#8217;s third-quarter revenue grew 8% YoY to $38.38 billion, surpassing analyst estimates, while adjusted earnings per ADS of $2.93 beat consensus expectations of $2.66. The revenue for Alibaba's Cloud Intelligence Group witnessed a 13% year-on-year growth to $4.37 billion with revenue from AI-related products experiencing triple-digit growth for the sixth straight quarter.
The company&#8217;s CEO Eddie Wu&nbsp;stated, "This quarter's results demonstrated substantial progress in our ‘user first, AI-driven' strategies and the re-accelerated growth of our core businesses.&#8221;
Also, during the company&#8217;s third-quarter earnings call, CFO, Toby Xu, confirmed the 5% net reduction in share count. The Chinese tech behemoth repurchased $1.3 billion of its shares in the December quarter. This follows an approximate $10 billion in buybacks during the first half of fiscal 2024. The company still has $20.7 billion left in its buyback authorization. The buyback strategy was implemented as Alibaba reported $83.6 billion in cash reserves as of Dec. 31. 
SEE ALSO: <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">Tesla&#8217;s Refreshed Model Y Rolls Off Shanghai Gigafactory, Deliveries To Start &#8216;Soon&#8217;</a>
Why It Matters: The stock has&nbsp;seen nearly an 80% surge over the past 12 months,&nbsp;bolstered by China&#8217;s&nbsp;economic stimulus measures and growing&nbsp;traction in Alibaba&#8217;s AI offerings. This growth in <a href="https://www.benzinga.com/25/02/43874037/alibaba-sees-ai-gold-rush-in-cloud-computing-not-open-and-closed-source-modelshints-monetization-lies-in-powering-ai-not-selling-it">AI offerings aligns with the company&#8217;s belief</a> that the real value in artificial intelligence will come from cloud infrastructure rather than the models themselves.
Moreover, CEO&nbsp;Eddie Wu&nbsp;revealed expectations that the company's International Commerce Unit would achieve profitability in the next fiscal year.
Meanwhile, Alibaba&#8217;s&nbsp;board-level capital management committee also continues&nbsp;to manage&nbsp;shareholder return initiatives through a&nbsp;mix&nbsp;of dividends, share buybacks, and&nbsp;strategic investments. 
The stock also surged in Hong Kong market on Friday as economists predict China's central bank could lower its main policy rate in March
Alibaba&#8217;s&nbsp;ADR closed at $135.97 on&nbsp;Thursday, gaining 8.09% for the&nbsp;day. In after-hours trading, the&nbsp;stock rose an additional 0.82%.&nbsp;Year to date, Alibaba shares&nbsp;have surged 60.06%, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/02/43805852/trump-shakes-global-trade-with-25-auto-chip-and-pharma-tariffs-announcement-asian-stocks-pare-their-five-day-rally">Trump Announces 25% Tariff On Auto Imports, Chips And Pharmaceuticals, Shaking Global Trade: Nvidia, Apple, TSMC And Others In Focus</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
&nbsp;

Tech

BABA Stock Climbs Over 4% In Friday Pre-Market: What's Going On?

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/21060806/brk7e-s4eqp.png" alt="" class="wp-image-6173" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/21060806/brk7e-s4eqp.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/21060806/brk7e-s4eqp-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/21060806/brk7e-s4eqp-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
A Chinese biotech that made a name for itself by co-developing an anti-Covid drug has filed for a stock market listing to fund research into tackling other conditions
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>Vigonvita works closely with the Chinese Academy of Sciences through its founder and biggest shareholder, research scientist Shen Jingshan</li>
<li>After selling rights to its flagship anti-viral product, the drug developer fell back into the red last year</li>
</ul>
As Chinese biotechs beat a path to Hong Kong's IPO market, hoping to catch the eye of investors, one drug developer can point to a commercially launched Covid treatment as proof of its capability.
Vigonvita Life Sciences Co. Ltd., in partnership with Chinese research institutes, began work on the oral anti-viral medicine during the pandemic, later selling the product rights to a major Chinese pharmaceutical brand.
The pandemic project raised the company's profile and is now being leveraged in its pursuit of a Hong Kong stock listing.
Before the Chinese New Year holiday, the developer of innovative drugs&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107116/documents/sehk25012700686.pdf">applied</a>&nbsp;to join the main board of the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor.
Founded in 2013, Vigonvita Life Sciences develops small molecule drugs to treat viral infections, mental health disorders and reproductive issues. Its pipeline contains nine innovative drugs as well as four generic drugs, two of which have gained marketing approval, bringing new revenue streams into the company.
Vigonvita's activities extend from drug research and development to manufacturing and sales. Its founder and biggest shareholder, Shen Jingshan, is a leading researcher and doctoral supervisor at a Shanghai institute within the Chinese Academy of Sciences that was involved in developing the Covid drug.
After the pandemic broke out in 2020, Vigonvita collaborated with Chinese research bodies to develop anti-Covid medicines, acquiring exclusive intellectual property rights to the resulting treatment, VV116.
In September 2021, Vigonvita sold the rights to develop, manufacture, and commercialize the product in most parts of the world to&nbsp;Junshi Biosciences&nbsp;(1877.HK; 688180.SH), while the right to supply the active ingredients was transferred to a pharmaceutical company based in Hainan province.
Together, the two out-licensing deals boosted Vigonvita's finances. China granted conditional marketing approval for the drug in January 2023 and folded it into the national medical insurance system a year later, although by then the pandemic had subsided.
The drug brought in revenues of 110 million yuan ($15.02 million) in the first half of 2023, according to earnings data from Junshi Biosciences, but after that the company stopped releasing specific product figures. Vigonvita is currently working on widening the clinical use of VV116 to cover respiratory syncytial virus (RSV) infections in children. Phase Three clinical trials are expected to be launched in the third quarter of 2025.
The research alliance that produced the Covid drug has also developed two other candidate treatments for which Vigonvita holds the intellectual property rights. According to the IPO prospectus, the company's co-founder and second biggest shareholder, Tian Guanghui, played a key role in developing the two drugs, LV232 and TPN171.
The first of those, a treatment for depression, will enter Phase Two trials in China in the first quarter of 2025. The company expects its TPN171 drug for erectile dysfunction to get marketing clearance in China in the middle of this year, after it was already approved in Uzbekistan. The income would be a welcome boost for the company, after revenues plunged last year.
<h4 class="wp-block-heading">Falling from a high base</h4>
Product sales have not been the company's main source of revenue. Instead, the bulk of the firm's earnings come from licensing deals, contract research services and pharmaceutical sales. On that basis the company brought in 190 million yuan in 2023 and revenues of 10 million yuan in the first nine months of 2024, but it made a net profit of just 48.51 million yuan and a loss of 151 million yuan in the two periods.
The prospectus blamed the sharp drop on a high base effect, after the previous year's earnings had been boosted by milestone payments and the sale of rights relating to VV116. An analysis of the firm's top five revenue sources shows 102 million yuan coming from Junshi Biosciences in 2023, and payments from the supplier of active ingredients amounting to 94.34 million yuan. But in the first three quarters of last year the input from Junshi Biosciences was a mere 7.98 million yuan and there was no payment from the other partner.
With licensing money drying up, Vigonvita quickly fell back into the red, although its research credentials helped it maintain access to capital. The company completed five rounds of financing between 2020 and 2024. The Series B financing in April 2022 boosted the firm's valuation to 4.2 billion yuan from 1.57 billion yuan four months earlier. The last round of Series C in April 2024 brought in another 160 million yuan, pushing the value to 4.45 billion yuan.
Cash and cash equivalents held by Vigonvita had fallen to 95.05 million yuan at the end of September last year. In the absence of licensing revenue and more drug launches, the IPO is an opportunity for the company to replenish its coffers for future R&amp;D.

Asia

Biotech

IPOs

As Covid Drug Cash Dwindles, Vigonvita Targets New Remedies

Apple Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) AI-driven Visual Intelligence feature is reportedly coming to iPhone 15 Pro models in an upcoming iOS update.
What Happened: Apple Intelligence, the company's suite of AI-powered features, includes Visual Intelligence, which allows users to analyze objects, translate text, and search for information in real-time using their iPhone's camera.
While iPhone 16 and 16 Pro users can trigger the feature using a dedicated camera button, the iPhone 15 Pro and Pro Max and <a href="https://www.benzinga.com/tech/25/02/43820197/apple-unveils-iphone-16e-with-a18-chip-ai-features-599-price-tag">newly launched</a> iPhone 16e lack this hardware.
See Also: <a href="https://in.benzinga.com/markets/equities/25/02/43873396/apple-stock-has-run-up-over-10-in-a-month-jim-cramer-says-iphone-maker-is-ramping-and-the-credit-goes-to-chinese-subsidies">Apple Stock Has Run Up Over 10% In A Month, Jim Cramer Says iPhone Maker Is &#8216;Ramping&#8217; And The Credit Goes To Chinese Subsidies</a>
&#8220;Apple's solution to enable visual intelligence on the iPhone 16e, despite it lacking the Camera Control button, is two-fold. First, visual intelligence is now available in the Control Center. Second, as demonstrated by Apple in the announcement video, you can assign the Action Button to visual intelligence,&#8221; said Daring Fireball's John Gruber.
Gruber further said that Cupertino will likely assign Visual Intelligence to the Action button or use a Control Center shortcut, citing an Apple representative.
Apple hasn't confirmed which iOS version will bring Visual Intelligence to iPhone 15 Pro models, but Gruber speculates it may arrive in iOS 18.4, which could enter beta testing "any day now."
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Apple's decision to extend Visual Intelligence to iPhone 15 Pro users reduces the pressure to upgrade to the iPhone 16 series for AI-driven camera enhancements.
Since its launch in September 2023, the iPhone 15 Pro series has seen significant adoption, with the Pro and Pro Max models accounting for 5.44% and 6.83% of the market by November 2024, <a href="https://www.statista.com/statistics/1447263/iphone-15-adoption-rate-by-model-worldwide/?__sso_cookie_checker=failed">according</a> to Statista.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/25/02/43840286/apples-iphone-16e-to-drive-revenue-growth-for-tim-cooks-company-says-top-analyst">Apple&#8217;s iPhone 16e To Drive Revenue Growth For Tim Cook&#8217;s Company, Says Top Analyst</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Apple's Visual Intelligence May Come To iPhone 15 Pro: Here's How It Can Transform Your Camera With AI-Powered Real-Time Search

Vipshop Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) reported quarterly earnings of $5.70 per share which beat the analyst consensus estimate of $5.52 by 3.26 percent. This is a 595.12 percent increase over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $33.224 billion which beat the analyst consensus estimate of $32.102 billion by 3.49 percent. This is a 580.26 percent increase over sales of $4.884 billion the same period last year.

Earnings

Earnings Beats

VIPS

Vipshop Holdings Q4 2024 Adj. EPS $5.70 Beats $5.52 Estimate, Sales $33.224B Beat $32.102B Estimate

CRWD CLIMBS OVER 14 POINTS AFTER THE ALERT
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="891" height="632" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/20220650/Screen-Shot-2025-02-20-at-4.27.34-PM.png" alt="" class="wp-image-6162" style="width:920px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/20220650/Screen-Shot-2025-02-20-at-4.27.34-PM.png 891w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/20220650/Screen-Shot-2025-02-20-at-4.27.34-PM-300x213.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/20220650/Screen-Shot-2025-02-20-at-4.27.34-PM-768x545.png 768w" sizes="(max-width: 891px) 100vw, 891px" /></figure>
CrowdStrike Holdings, Inc. (CRWD) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:02 AM on February 20th, a significant trading signal occurred for CrowdStrike Holdings, Inc. (CRWD) as it demonstrated a Power Inflow at a price of $422.37. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in CrowdStrike&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in CrowdStrike&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for CRWD, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $422.37. The returns on the High price ($436.75) and Close price ($436.14)after the Power Inflow were respectively 3.4% and 3.3%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were very close but that is not always the case
Past Performance is Not Indicative of Future Results

Equities

Technicals

TRADEPULSE POWER ALERT: CROWDSTRIKE HOLDINGS INC.,CRWD,MOVES UP 3.4% AFTER ALERT FROM TRADEPULSE

Kash Patel, the newly confirmed Federal Bureau of Investigation director, has significant exposure to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), according to a financial disclosure.
What happened: Patel reported holding between $50,001 and $100,000 in the Grayscale Bitcoin Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#NYSE">GBTC</a>) and up to $15,000 in its &#8220;spin-off,&#8221; the Grayscale Bitcoin Mini Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTC#NYSE">BTC</a>).
Additionally, he owned a stake worth between $50,001 and $100,000 in leading Bitcoin mining firm Core Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>).
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43826697/bitcoin-early-in-bull-market-can-compete-with-gold-etfs-blockstream-ceo-says">Bitcoin &#8216;Early In Bull Market,&#8217; Can Compete With Gold ETFs, Blockstream CEO Says</a>
Why It Matters: The disclosure was the latest evidence of the involvement of high-ranking officials of the Donald Trump administration in cryptocurrency.&nbsp;&nbsp;
Apart from the president, who holds a significant amount of Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>), <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42936887/trumps-treasury-pick-scott-bessent-reveals-up-to-500000-bitcoin-stake-via-blackrocks-etf">Treasury Secretary</a> Scott Bessent, Health Secretary Robert F. Kennedy Jr., and <a href="https://www.benzinga.com/general/market-summary/25/02/43809086/us-commerce-secretary-howard-lutnicks-cantor-fitzgerald-increases-bitcoin-exposure-via-etfs-mstr-mara-adds-chinese-firms-like-baba-baidu-jd-in-q4">Commerce Secretary</a> Howard Lutnick have invested in digital assets.
Patel, who was confirmed as FBI director by the Senate on Thursday, previously worked for Trump on the National Security Council in 2019. He also helped with the Pentagon transition effort from Trump to Biden.
Moreover, Patel <a href="https://www.benzinga.com/politics/24/12/42278429/trump-fbi-pick-kash-patels-wealth-has-grown-from-trump-media-board-position-consulting-deal-and-trump-themed-childrens-books">served as a director</a> on the board of Trump Media &amp; Technology Group, which was co-founded by Trump. In the disclosure, Patel said he would terminate the position before taking charge as the FBI director.
Price Action: At the time of writing, Bitcoin was exchanging hands at $98,300.91 up 1.16% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43825637/donald-trump-says-us-is-successfully-negotiating-with-russia-over-ukraine-but-polymarket-traders-arent-convinced">Donald Trump Says US Is &#8216;Successfully Negotiating With Russia&#8217; Over Ukraine, But Polymarket Traders Aren&#8217;t Convinced</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

Core Scientific, Inc. - Class A Common Stock

CORZ

GBTC

TSX:ETF

New FBI Director Kash Patel Holds Over $100,000 In Bitcoin ETFs, Has Significant Exposure To BTC Miner Core Scientific

Comments

Viridien ADR

Viridien ADR (CGGYY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga